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2Abstract
Damage to the vasculature is the primary mechanism driving chronic diabetic microvascular 
complications such as diabetic nephropathy which manifests as albuminuria. Therefore, 
treatments that protect the diabetic vasculature have significant therapeutic potential. Soluble 
Neurite outgrowth inhibitor-B (sNogo-B) is a circulating N-terminus isoform of full-length 
Nogo-B which plays a key role in vascular remodelling following injury. However, there is 
currently no information on the role of sNogo-B in the context of diabetic nephropathy. We 
demonstrate that overexpression of sNogo-B in the circulation ameliorates diabetic kidney 
disease by reducing albuminuria, hyperfiltration, abnormal angiogenesis and protecting 
glomerular capillary structure. Systemic sNogo-B overexpression in diabetic mice also 
associates with dampening VEGF-A signalling and reducing eNOS, AKT and GSK3β 
phosphorylation. Furthermore, sNogo-B prevented the impairment of tube formation which 
occurred when human endothelial cells were exposed to sera from patients with diabetic 
kidney disease. Collectively, these studies provide the first evidence that sNogo-B protects 
the vasculature in diabetes and may represent a novel therapeutic target for diabetic vascular 
complications.
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3Diabetic nephropathy (DN), the leading cause of end-stage renal disease in the Western 
world, is characterised by structural changes in the kidney glomerular filtration barrier (1; 2). 
This leads to enhanced glomerular permeability manifested as albuminuria, representing a 
common mechanism for renal and extrarenal diabetic vascular complications (3).
A complex network of vascular growth factors regulates the permeability and structure of the 
glomerular capillary filtration barrier (4). Glomerular levels of vascular endothelial growth 
factor-A (VEGF-A) and angiopoietin-2 (Angpt2) are upregulated in the early stages of DN 
whilst angiopoietin-1 (Angpt1) is downregulated (5-7); a milieu associated with vascular 
remodelling, endothelial proliferation and increased capillary permeability (1; 4). Blockade of 
VEGF-A signalling (8) or restoration of Angpt1 levels in podocytes (7) ameliorates albuminuria 
and glomerular damage in rodent models of early DN. The effects of vascular growth factors 
on endothelial permeability in DN are partly mediated by nitric oxide (NO) signalling through 
modulation of endothelial nitric oxide phosphorylation (eNOSSer1177) which acts in an AKT-
dependent manner (9). In diabetes, reduction in NO availability due to eNOS uncoupling (10) 
has been implicated in the pathophysiology of DN. Podocyte-specific overexpression of 
Angpt1 activates eNOS (7) in diabetic mice, whilst the beneficial effect of VEGF-A blockade 
on albuminuria in DN is prevented in eNOS knock-out mice (11).
Another pathway involved in vascular remodelling is the neurite outgrowth inhibitor (Nogo) 
family which is encoded by one gene with three major isoforms: Nogo-A, -B and -C (12), 
mainly expressed in the endoplasmic reticulum (ER)(13). Nogo-A and -C are found in the 
central nervous system and muscle tissue respectively, whilst Nogo-B localises to endothelial 
and smooth muscle cells within the vasculature (12). In physiology, loss of Nogo-B 
upregulates eNOS-NO and flow-mediated vasodilation, leading to hypotension (14). Mice 
lacking both Nogo-A and B are viable and do not have major apparent vascular defects (15). 
However, vascular lesions are enhanced in Nogo A/B deficient mice following injury which can 
be prevented by gene delivery of full-length Nogo-B (15; 16).
The full-length Nogo-B protein of 49 kDa can be cleaved into a shorter ~150-aa N-terminus 
fragment (17) which can then be secreted into the circulation as soluble Nogo-B (sNogo-
B)(18). This Nogo-B N-terminus (identical in circulating sNogo-B and full-length Nogo-B within 
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4the cells) binds to its receptor NgBR, expressed in endothelial cells on the cell plasma 
membrane and in the ER leading to endothelial cell proliferation/vascular remodelling (15; 19), 
angiogenesis during development, vascular repair, and cytoskeletal organisation (12; 20-23). 
Given the role of this N-terminal fragment of Nogo-B in vascular remodelling, we hypothesised 
that overexpression of sNogo-B in the circulation could have a protective role in the setting of 
diabetic kidney disease.
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5Research design and methods
Materials and chemicals were purchased from Sigma (Gillingham, UK) and Starlab (Milton 
Keynes, UK) unless otherwise stated.
Experimental animal model of diabetes
To induce diabetes, 8-10 week old (~20g in weight) male DBA2J mice were administered with 
streptozotocin (low dose multiple injection protocol)(7; 8). Mice were considered diabetic with 
a fed glycemia >22 mmol/l.  Control non-diabetic littermates were injected with vehicle only 
(citrate buffer). Two weeks later, some diabetic and non-diabetic mice were administered an 
Adeno Associated viral Vector expressing 6xHis-Tag/sNogo-B (AAV-sNogo-B)(Supplemental 
Material, Fig. 1a). The utilised vector, AAV/DJ, has a specific tropism for the liver and 
maintains a sustained expression of transgene for 15-17 weeks under the CMV promoter (24). 
The construct also contains a secretory alkaline phosphatase peptide, which drives the release 
of the 6xHis-Tag/sNogo-B protein in the circulation. To control for infection, other diabetic and 
non-diabetic mice were injected with AAV/DJ driving the expression of green fluorescent 
protein (GFP) under the same promoter (AAV-GFP).
All mice were maintained for 12-14 weeks after induction of diabetes before sacrifice and 
tissues analysis. Prior to sacrifice, blood pressure was assessed with tail cuff methodology, 
and 24h-urine collection was conducted with mice kept in metabolic cages for creatinine, 
sNogo-B and albuminuria determination (7). At sacrifice full blood and plasma was collected 
(to assess for HbA1c, creatinine by high performance liquid chromatography, and sNogo-B 
levels). Kidney tissue was harvested for histology, electron microscopy (EM), and lysates of 
kidney cortex or isolated glomeruli frozen for further analysis (7).
Immunofluorescence
Proliferating glomerular ECs (GECs) determination
Glomerular Ki67/CD31 and CD31-positive GECs per glomerulus were visualised with 
fluorescent microscope (7); an average of 30-40 glomeruli per animal were studied and the 
means values utilised in the analysis.
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6Endothelial glycocalyx determination
Lectin staining was assessed as indicator of thickness/integrity of the endothelial glycocalyx in 
frozen kidney sections as described (25). A total of 10-15 capillary loops were analysed per 
mouse from 5-7 glomeruli and the mean value for each animal was utilised in the analysis.
Electron microscopy and glomerular ultrastructure analysis
Mesangial volume fraction, GBM thickening, podocyte number and glomerular volume were 
studied as described (7; 8). For detailed methodology see Supplemental Material.
sNogo, VEGF-A, Angpt1/2 and VEGFR2Tyr1173 phosphorylation ELISA
sNogo-B in plasma, urine and cell culture media was assessed by ELISA (BioLegend, San 
Diego, CA, USA). ELISA was also utilised for kidney cortex VEGF-A (R&D Systems, 
Abingdon, UK), Angpt1/2 (Biomatick, Wilmington, DE, USA) and VEGFR2 phosphorylation 
(PathScan, Cell Signalling, Leiden, The Netherlands) levels; results were normalised for mcg 
of total kidney cortex protein lysates.
Immunoblotting
Immunoblotting was performed on cells and tissues lysates (mouse renal cortex and isolated 
glomeruli) as described (7). The following primary antibodies were utilised: Nogo-B (N-
terminus, R&D System, Abingdon, UK); NgBR (Abcam, Cambridge, UK); -tubulin (Santa 
Cruz Biotechnology, Heidelberg, Germany); -actin; pan-AKT, GSK3β, phospho-AKT (Ser473), 
phospho-eNOS (Ser1177), and phospho-GSK3βSer9 (Cell Signalling, Leiden, The Netherlands); 
eNOS (Santa Cruz Biotechnology, Heidelberg, Germany); total β-catenin (Proteintech, 
Manchester, UK).
Culture of mouse lung endothelial cells, human GECs, and human podocytes
Primary lung ECs were isolated from adult C57BL/6J mice and cultured, up to three passages, 
as described (14).
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7Human GECs and podocytes were cultured as described (26; 27). To examine the effect of 
high glucose and VEGF-A in fully differentiated GECs, cells were starved for 12h in 1% serum 
followed by incubation in normal glucose (5 mmol/l glucose+20 mmol/l mannitol) or high 
glucose (25 mmol/l glucose) for 72h in the presence or absence of VEGF-A (50 ng/ml).
Immunoprecipitation (IP) and proximity ligation assay (PLA) experiments
For IP experiments, GEC were transfected with 6xHis-Tag/sNogo-B adenovirus (ADV-sNogo-
B - transgene identical to the AAV-sNogo-B construct) at 100 multiplicity of infection (MOI) for 
4h and studied after 24h; whole protein lysates were obtained and incubated with either anti 
NgBR (Novus Biological, Oxford, UK), or anti 6xHis-Tag antisera (ThermoFisher Scientific, 
Oxford, UK), or vehicle IgG. Immunoblotting was conducted on immunoprecipitates obtained 
with anti-6xHis-Tag and -NgBR antisera.
For the PLA experiments cell culture media enriched with 6xHis-Tag/sNogo-B was obtained 
by transfecting confluent human GECs with ADV-sNogo-B (100 MOI) in full media for 4h; 
subsequently cells were put in 1% serum media and supernatant (containing 6xHis-
Tag/sNogo-B protein, ~6000 pg/ml) collected after 48h; collected media was stored at 4°C 
and utilised within 6-12h. Human differentiated GECs were then incubated with “6xHis-
Tag/sNogo-B conditioned media” for 1, 5 and 15min, fixed in 4% paraformaldehyde for 10min, 
and then incubated with primary antisera against NgBR (1:100 dilution, rabbit anti N-terminus 
NgBR, gift from R. Miao), and anti 6xHis-Tag (1:100 dilution) mouse monoclonal antiserum 
(ThermoFisher Scientific, Oxford, UK). The NgBR-sNogo-B interaction was visualised with 
immunofluorescence following manufacturer instructions (Duolink® In Situ Red Starter Kit 
Mouse/Rabbit).
Nogo-B immunogold staining in glomeruli
Nogo-B immunogold staining was conducted in mouse renal cortex tissue as previously 
described using a sheep polyclonal anti-Nogo-B (N-terminus) antibody (R&D System, 
Abingdon, UK)(8).
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8Nogo-B immunohistochemistry 
Nogo-B immunohistochemistry was conducted in mouse and human (patients with DN or thin 
basement membrane nephropathy-TBMN)(Supplemental Material, Table 1) kidney tissue 
paraffin sections using the streptavidin-biotin complex method with specific sheep polyclonal 
anti Nogo-B N-terminus antibody (R&D System, Abingdon, UK).
In human tissue, Nogo-B expression was quantified by assessing the % glomerular area with 
positive staining. Ten glomeruli were analysed for each human biopsy and the calculated 
average Nogo-B staining/area of glomeruli was then used for analysis.
Role of sNogo-B overexpression in human umbilical vein endothelial cells (HUVEC) tube 
formation assay
To examine the continuous paracrine/autocrine effect of sNogo-B on angiogenesis, HUVEC 
were transfected with ADV-sNogo-B or identical vector lacking sNogo-B cDNA (control vector)( 
Supplemental Material, Fig. 1b) for 4h; cells were then equilibrated (24h) in complete medium 
and then plated in 96 well plates (5000 cells/well) in EGM basal media containing sera (4% 
vol/vol) obtained from patients with type-1 diabetes (T1DM) susceptible (DN+) or protected 
(DN-) towards the progression of DN (Supplemental Material, Table 2). Tube formation was 
performed on Matrigel (BD Biosciences, UK)(28) in duplicate and assessed after 24h. Tube 
length and number were analysed in a blinded fashion with the Wimasis WimTube image 
system (29).
Statistical Methods
Differences among groups were analysed by two tails Student’s t-test or ANOVA with post-
hoc Least Significant Difference (LSD) pairwise comparisons test for normally distributed 
variables. Kruskal-Wallis and Mann-Whitney non-parametric tests were used for not normally 
distributed variables (albuminuria and sNogo-B). Data are expressed as means±standard 
deviation (SD) for normally distributed data or as median and interquartile range for not 
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9normally distributed data. Analysis was conducted with IBM SPSS-22 software (New York, 
NY, USA) and statistical significance was accepted at p≤0.05.
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Results
sNogo-B overexpression ameliorates diabetes-mediated albuminuria and hyperfiltration
Non-diabetic (ND) and diabetic (D) mice injected with AAV-sNogo-B were characterised by a 
12-fold increase in circulating sNogo-B when compared with those injected with control vector 
(AAV-GFP)(Fig. 1a, ND-GFP vs ND-sNogo-B, p=0.00001; D-GFP vs D-sNogo-B, p=0.0001).
Diabetes led to a significant increase in HbA1c levels (ND-GFP vs D-GFP, p=0.00008; ND-
sNogo-B vs D-sNogo-B, p=0.00004), which was paralleled by a loss of body weight (ND-GFP 
vs D-GFP, p=0.0001; ND-sNogo-B vs D-sNogo-B, p=0.00001), increased kidney/body weight 
ratio (ND-GFP vs D-GFP, p=0.006; ND-sNogo-B vs D-sNogo-B, p=0.0002) and a modest 
decrease in systolic blood pressure (ND-GFP vs D-GFP, p=0.01; ND-sNogo-B vs D-sNogo-
B, p=0.003)(Table 1).
Glomerular permeability, measured by albumin excretion rate over 24h urine collection, was 
increased in diabetic mice compared with non-diabetic mice (Fig. 1b, ND-GFP vs D-GFP, 
p=0.0001). Overexpression of sNogo-B in the circulation of diabetic mice led to a significant 
40-50% reduction in albuminuria (Fig. 1b, D-GFP vs D-sNogo-B, p=0.04). This effect was 
independent of changes in systemic blood pressure, kidney/body weight and glycaemic 
control which were similar in diabetic mice administered either AAV-sNogo-B or AAV-GFP 
(Table1). Diabetes-mediated renal hyperfiltration was evidenced by raised creatinine 
clearance levels (Fig. 1c, ND-GFP vs D-GFP, p=0.02) and AAV-sNogo-B overexpression 
attenuated this effect (Fig. 1c, D-GFP vs D-sNogo-B, p=0.04).
Urinary sNogo-B was measured in a subset of animals. Diabetes was paralleled by an 
increase in 24h-urine sNogo-B in both mice administered AAV-GFP or AAV-sNogoB (Fig. 1d, 
ND-GFP vs D GFP and ND-sNogo-B vs D-sNogo-B, p≤0.002); no differences were observed 
in urine sNogo-B between AAV-GFP or AAV-sNogo-B mice within the ND and D group.
Effects of sNogo-B overexpression on GECs and podocytes in diabetes
The results above implicate sNogo-B as having a protective role in glomerular capillary 
permeability in diabetic kidneys. We therefore explored whether elevated circulating levels of 
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sNogo-B might stabilise the glomerular vasculature and confer a healthier GEC and podocyte 
phenotype in diabetes.
Firstly, we examined GECs proliferation to assess the effect of sNogo-B on abnormal vascular 
remodelling that occurs in early diabetic glomerulopathy (Fig. 2a, b)(1; 7). Diabetes increased 
the number of CD31+/Ki67+ cells per glomerulus by 7-fold which was attenuated in mice with 
sNogo-B overexpression in the circulation (Fig. 2b, ND-GFP vs D-GFP, p=0.0001; D-GFP vs 
D-sNogo-B, p=0.005). The total number of CD31+ cells/glomeruli was not different between 
animals with increased sNogo-B in the circulation in either non-diabetic and diabetic mice 
(mean±SD CD31+ cells/glomeruli: ND-GFP 7.6±1.37, ND-sNogo-B 7.7±1.8, D-GFP 9.7±2.4, 
D-sNogo-B 9.5±3.0, n=7 animals per group, p=ns).
We performed lectin staining as an indicator of thickness/integrity of the glomerular endothelial 
glycocalyx, which is known to contribute to vascular permeability (30). The estimated lectin 
thickness was significantly reduced in diabetic mice but restored to base-line levels in mice 
administered AAV-sNogo-B (Fig. 2c, ND-GFP vs D-GFP p=0.009; D-GFP vs D-sNogo-B, 
p=0.0004).
Using EM (Supplementary Material, Fig. 2), we found that diabetes was also paralleled by 
a significant decrease in the number of podocytes per glomerulus (Fig. 2d, ND-GFP vs D-
GFP p=0.0002), increased the mesangial volume fraction (Fig. 2e, ND-GFP vs D-GFP 
p=0.02) but had no effect on glomerular basement membrane (GBM) width (Fig. 2f) or 
glomerular volume (Table 1). The reduction in podocyte number observed in diabetic mice 
was ameliorated by elevated circulating sNogo-B levels (Fig. 2d, D-GFP vs D-sNogo-B, 
p=0.01). Overexpression of sNogo-B in the circulation did not alter diabetes-mesangial 
expansion (Fig. 2e), GBM width (Fig. 2f), or glomerular volume in diabetic mice (Table 1).
Effects of sNogo-B overexpression in the circulation on vascular growth factors, eNOS, AKT 
and GSK3β signalling in the kidney cortex
To identify the molecular mechanisms by which sNogo-B might alter the endothelium in 
diabetes, we examined levels of the vascular growth factors VEGF-A, Angpt1 and Angpt2 in 
kidney cortex lysates. VEGF-A protein levels were significantly increased in diabetic mice (Fig. 
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3a, ND-GFP vs D-GFP, p=0.009) and were reduced when sNogo-B was overexpressed in the 
circulation (Fig. 3a, D-GFP vs D-sNogo-B, p=0.03).
In accord with these findings, phosphorylation levels of the main VEGF-A receptor, VEGFR2, 
in the kidney cortex were significantly elevated in diabetic mice; an effect which was 
dampened in mice with elevated circulating sNogo-B levels (Fig. 3b, ND-GFP vs D-GFP, 
p=0.003; D-GFP vs D-sNogo-B, p=0.01). Angpt1/Angpt2 ratio was lower in diabetic mice and 
was not altered by sNogo-B overexpression in the circulation (Fig. 3c, ND-GFP vs D-GFP, 
p=0.03; ND-sNogo-B vs D-sNogo-B, p=0.001).
Given that upregulation of sNogo-B in the circulation was paralleled by altered VEGF-A 
signalling, whose effects on endothelial permeability in DN are regulated by eNOS activation 
(9), we examined phosphorylation of eNOS. Diabetes led to a significant increase in the ratio 
of phosphorylated eNOSsSer1177/total eNOS (Fig. 3d-e, ND-GFP vs D-GFP, p=0.017) which 
was prevented by sNogo-B overexpression (Fig. 3d-e, D-GFP vs D-sNogo-B, p=0.05). As 
protein kinase B (AKT) activation is involved in endothelial cell proliferation and eNOS 
phosphorylation (9) we investigated the phosphorylation at the AKTSer473 site. The ratio of 
AKTSer473 phosphorylation/total AKT was upregulated in diabetic mice; an effect which was 
significantly attenuated in mice injected with AAV-sNogo-B (Fig. 4a, ND-GFP vs D-GFP, 
p=0.0001; D-GFP vs D-sNogo-B, p=0.04). The level of total AKT protein was downregulated 
by diabetes (ND-GFP vs D-GFP, p=0.002)(31), but elevated circulating levels of sNogo-B had 
no effect on total AKT protein expression in kidney cortex lysate.
We then investigated activation of GSK3β, a known substrate of AKT (32), that has been 
postulated as a therapeutic target for diabetic glomerulopathy (33). The ratio of 
phosphorylated GSK3βSer9/total GSK3β was upregulated in kidney cortex lysates of diabetic 
mice when compared with non-diabetic mice (Fig. 4b, ND-GFP vs D-GFP, p=0.006) 
consistent with previous reports (33). Notably, sNogo-B overexpression in the circulation was 
paralleled by a significant downregulation of GSK3βSer9 phosphorylation/total GSK3β in 
diabetic mice (Fig. 4b, D-GFP vs D-sNogo-B, p=0.04). Total GSK3β protein expression was 
not altered in any of the experimental groups studied. As a known substrate of GSK3β, and 
important player in DN (34), we studied total β-catenin (35) protein levels in kidney cortex 
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lysate. In line with GSK3β activation status, β-catenin was significantly upregulated in diabetic 
mice when compared to non-diabetic mice (Fig. 4c, ND-GFP vs D-GFP, p=0.007). sNogo-B 
overexpression in the circulation led to a significant downregulation of β-catenin in kidney 
cortex of diabetic mice, (Fig. 4c, D-GFP vs D-sNogo-B, p=0.01), whereas β-catenin protein 
levels were unaffected in non-diabetic animals.
sNogo-B binds to NgBR in human GECs in vitro.
Next, we examined the physical interaction between sNogo-B and NgBR by IP and PLA 
experiments in human GECs (26). Firstly, we showed that GECs expressed NgBR in vitro. 
We then could detect an interaction between 6xHis-Tag/sNogo-B and NgBR with IP 
experiments (Supplemental Material, Fig. 3a).
The sNogo-B/NgBR interaction was further confirmed with PLA experiments where the 
sNogo-B/NgBR interaction was observed by identification of positive red/orange dots signals 
in GECs incubated with “conditioned media” containing sNogo-B protein as early as 1min 
(Supplemental Material, Fig. 3b).
Renal cortical levels of full-length Nogo-B are downregulated in an animal model of diabetes 
and restored by sNogo-B overexpression in the circulation
To further explore the reno-protective mechanisms of sNogo-B overexpression in the 
circulation we investigated the expression of full-length Nogo-B in mouse and human kidney 
tissue in diabetes. With immunogold staining, combined with electron microscopy, we found 
that full-length Nogo-B protein was localised in both GECs and podocytes in non-diabetic male 
adult mice (Fig. 5a). Immunohistochemical staining confirmed the expression of full-length 
Nogo-B in the glomerular tuft and, as described, in cortical collecting duct (Fig. 5b)(36). Full-
length Nogo-B protein, assessed by immunoblotting, in glomeruli enriched kidney cortex and 
isolated glomeruli lysates was 2-3-fold downregulated in diabetic mice when compared with 
non-diabetic controls (Fig. 5c, ND-GFP vs D-GFP, p≤0.045); sNogo-B overexpression in the 
circulation restored the diabetes-induced loss of full length Nogo-B (Fig. 5c, D-GFP vs D-
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sNogo-B, p≤0.015). NgBR was expressed in isolated glomeruli but not modulated by diabetes 
or elevated sNogo-B circulating levels (Fig. 5d).
We also investigated the expression of full-length Nogo-B in human kidney biopsies obtained 
from two distinct glomerular diseases: DN and TBMN. DN represents a progressive proteinuric 
disease, while TBMN represents a benign non-proteinuric, non-progressive disorder, featuring  
a uniformly thinned GBM (37) without any other significant glomerular pathology 
(Supplemental Material, Table 1). Nogo-B expression was lower in glomeruli of kidney 
biopsies of patients with DN when compared with patients with TBMN (Fig. 5e, TBMN vs DN, 
p=0.0001).
High glucose and VEGF-A promote full-length Nogo-B downregulation and increased sNogo-
B secretion in the supernatant of GECs in culture
Fully differentiated human GECs (26) incubated in normal (NG) or high glucose (HG) condition, 
with VEGF-A (50 ng/ml, or vehicle) or a combination of HG and VEGF-A for 72h, showed a 30-
40% downregulation of full-length Nogo-B expression (NG vs HG, NG vs VEGF-A, NG vs 
HG+VEGF-A, p≤0.04)(Fig. 6a). HG and/or VEGF-A-mediated full length Nogo-B 
downregulation was paralleled by an upregulation of sNogo-B secretion in the supernatant (NG 
vs HG, NG vs VEGF-A, NG vs HG+VEGF-A, p≤0.03)(Fig. 6b).
sNogo-B overexpression corrects altered tube formation seen in HUVEC cultured with 
T1DM/DN+ serum
Finally, we explored the paracrine/autocrine effects of secreted sNogo-B overexpression on 
the ability of HUVEC, known to express NgBR (19), to differentiate in a tube-like structure 
(tube formation assay)(38) when incubated with the serum of patients with T1DM with (DN+) 
or without (DN-) DN (Supplemental Material, Table 2).
sNogo-B overexpression led to a 5-fold increase in sNogo-B released from cells into the 
supernatant when compared with ADV-control transfected cells (Fig. 7d, ADV-control vs 
ADV-sNogo-B within DN- and DN+, p=0.0001).
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HUVECs incubated with serum of patients with T1DM/DN+ had decreased numbers and 
lengths of tubes when compared to cells incubated with serum of patients with T1DM/DN- 
(Fig. 7a, b, c, ADV-control, DN- vs DN+, tube length p=0.01, tube number p=0.04). Increased 
sNogo-B in the supernatant was paralleled by a correction of the impaired tube formation 
observed in cells incubated with DN+ serum (Fig. 7a, b, c, DN+, ADV-control vs ADV-sNogo-
B, tube length p=0.02, tube number p=0.001).
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Discussion
In this study, we demonstrated, in DBA2/J diabetic mice, that systemic overexpression of the 
N-terminal fragment sNogo-B, which binds to NgBR, improved diabetic glomerulopathy as 
evidenced by a reduction in albuminuria. This finding was associated with reduced GECs 
proliferation, restoration of glycocalyx thickness, maintenance of podocyte number and 
dampening of VEGF-A signalling and eNOS, AKT and GSK3β phosphorylation as assessed 
in glomeruli enriched kidney cortex lysates. Finally, sNogo-B prevented the impairment of tube 
formation which occurred when endothelial cells were exposed to sera from T1DM patients 
with DN.
The reduction in diabetes-mediated albuminuria seen in mice with sNogo-B overexpression 
in the circulation was possibly partly driven by a parallel fall in diabetes-mediated glomerular 
hyperfiltration; this was not accompanied by an  increase in glomerular volume, which is in 
accord with other reports examining the early (up to 16 weeks of diabetes) phase of DN in 
DBA2J mice (39). Other potential confounders for the reduced albuminuria could be that 
sNogo-B overexpression in the circulation lowers blood pressure or be related to changes in 
glycaemic control (2). However, we did not find any change in systemic blood pressure or 
glycaemic control between diabetic mice with overexpression of sNogo-B in the circulation or 
control mice ruling out these possibilities. As previously described the blood pressure 
observed in diabetic DBA2J mice was slightly lower than in non-diabetic ones (39).
Urinary sNogo-B was elevated in diabetes, likely due to the increased permeability of the 
filtration barrier. However, the excretion of sNogo-B was not increased in either non-diabetic 
or diabetic mice administered AAV-sNogoB; a finding most likely to be attributed to the large 
molecular weight of the 6xHis-Tag/sNogo-B (~80 kDa, Supplemental Material, Fig. 1c). 
As albuminuria results from defects in the glomerular filtration barrier, we initially focussed on 
the glomerular endothelium since the biological effects of sNogo-B and its receptor NgBR are 
primarily on the vasculature (14; 19). Elevated circulating levels of sNogo-B prevented 
diabetes-mediated glomerular endothelial cell proliferation as seen in the early stages of DN 
(1; 7; 40). sNogo-B overexpression in the circulation was also associated with amelioration of 
the diabetes-induced loss of lectin, an important component of the endothelial glycocalyx, 
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known to contribute to vascular permeability (25; 41). These changes were paralleled by a 
reduction in VEGF-A signalling. VEGF-A is a potent stimulator of endothelial cell proliferation 
(42) and dampening VEGF-A signalling ameliorates albuminuria and glomerular damage in 
DN (4). VEGF-A has also been implicated in the regulation of the thickness of the endothelial 
glycocalyx in diabetic mice with the anti-angiogenic VEGF-A165b isoform able to restore the 
diabetes-induced loss of the endothelial glycocalyx and albuminuria (41).  There have been a 
few reports linking the sNogo-B/NgBR and VEGF-A/VEGFR2 systems suggesting a 
concerted vasculoprotective role (20; 43).
The effects on the endothelium may also be related to the changes seen in Wnt/β-catenin 
signalling. Activation of Wnt/β-catenin signaling (with cellular β-catenin accumulation) results 
in endothelial dysfunction, inflammation and fibrosis, and has been implicated in DN (34). 
Inactive GSK3β is also known to promote endothelial cell proliferation (44), with a 
phosphorylated (inactive) GSK3β favouring accumulation of cellular β-catenin (45), a 
promoter of angiogenesis and enhancer of VEGF-A/VEGFR2 signaling (46). In our 
experiments, we showed that sNogo-B reduced GSK3β phosphorylation/β-catenin which may 
contribute to preventing the angiogenesis response to diabetes-mediated vascular damage 
and dampen VEGF-A/VEGFR-2 signalling.
Increased eNOS phosphorylation and NO production have been implicated in hyperfiltration 
in the early phases of diabetic glomerulopathy (47; 48), and the role of eNOS in oxidative 
stress (when in an “uncoupled state”(49)) is implicated in DN and GECs/podocyte damage 
(50). The reduction in diabetes-mediated eNOS phosphorylation, observed in kidney cortex 
lysates of diabetic mice with elevated sNogo-B circulating levels, would result in reduced 
eNOS-mediated NO production and oxidative stress; events that could contribute to a 
reduction in glomerular hyperfiltration (51) and in the prevention of diabetes-mediated loss of 
GECs glycocalyx and podocyte detachment. sNogo-B overexpression in the circulation 
associates with inhibition of diabetes-mediated modulation of VEGF-A/VEGFR2 and 
AKT/GSK3β/β-catenin system, signalling pathways which are implicated in podocyte 
injury/detachment and albuminuria (52-54). Finally, it might be possible that sNogo-B may 
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have a direct effect on podocytes as evidenced by our in vitro data showing expression of 
NgBR in human podocyte cells (Supplemental Material, Fig. 4).
Full-length Nogo-B (assessed with specific N-Terminus antiserum) was found to be expressed 
in isolated glomeruli and glomeruli enriched kidney cortex lysates and downregulated in 
diabetic mice. Full-length Nogo-B expression levels were also lower in glomeruli of proteinuric 
DN (a progressive chronic kidney disease) biopsy kidney samples when compared with 
TBMN, a benign glomerular disease without proteinuria, suggesting that the presence of 
proteinuria/albuminuria associates with reduced glomerular full-length Nogo-B levels. 
Whether low glomerular Nogo-B causes albuminuria is yet to be determined, but in 
experimental models of diabetic retinopathy lack of full-length Nogo-B attenuated high glucose 
induced cell migration and tube formation (EC differentiation)(55). In contrast to our findings, 
studies performed in humans’ and rodents’ renal biopsies (NephroSeq database, University 
of Michigan, USA), showed no change in full-length Nogo-B mRNA expression in diabetic 
kidney tissue when compared with control tissue.
We also demonstrate that high glucose and/or VEGF-A determine, in GECs in culture, an 
increase in sNogo-B in the supernatant and a parallel reduction in cellular full length Nogo-B 
(probed with specific N-Terminus antiserum). These results support the cleavage of the full-
length Nogo-B N-Terminus as previously described (17) and future work will have to address 
the mechanisms behind this phenomenon.
We then explored the putative vasculo-protective role of sNogo-B in an angiogenesis 
experimental model in HUVEC cultured with sera of patients with T1DM susceptible (DN+) or 
protected (DN-) towards the progression of DN (56). We demonstrate that circulating factors 
(sera from T1DM/DN+), other than glucose, negatively affect ECs tube formation and sNogo-B 
overexpression in the supernatant rescued this defect favouring ECs differentiation towards a 
stable tube structure, an effect likely related to the patients’ “DN” status rather than being 
driven by renal impairment given that the average of renal function of the two groups of 
patients studied was 80-100 ml/min per 1.73m2. Importantly, artificial upregulation of the N-
terminus of Nogo-B (sNogo-B) in the supernatant is able, via a paracrine autocrine 
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mechanism, to ameliorate the ability of ECs to migrate and differentiate into tubule-like 
structures (38), which translates in a more stable vasculature.
Collectively, our studies provide the first evidence that a primary increase of sNogo-B in the 
circulation protects the glomerular vasculature in diabetes. More studies will need to further 
dissect sNogo-B mechanism/s of action and explore its potential benefit in diabetic animals 
with established kidney disease. sNogo-B could represent a novel targetable pathway for the 
treatment of diabetic chronic vascular complications.
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Table legend:
Table 1: DBA2J mice clinical and biochemical characteristic.
Clinical and biochemical characteristics in non-diabetic and diabetic DBA2/J mice overexpressing sNogo-B 
(sNogo-B) in the circulation or control vector (GFP). BW: body weight, SBP: systolic blood pressure. Data 
are expressed as mean±SD (ANOVA with post-hoc LSD: ND-GFP vs D-GFP, *p≤0.01; ND-sNogo-B vs D-
sNogo-B, **p≤0.003).
 non diabeticGFP
non diabetic
sNogo-B
diabetic
GFP
diabetic
sNogo-B
HbA1c %(mmol/mol)
(n=16-17/group) 4.5 (26) ± 1.7 (18) 4.3 (24) ± 1.5 (15) 7.7 (60) ± 2.2 (24)* 7.5 (59) ± 2.8 (30)**
BW (g)   
(n=18-20/group) 28.6 ± 2.9 27.5 ± 3.56 23.6 ± 3.9* 21.6±4.4**
SBP (mmHg)
(n=7-10/group) 112 ± 11 111 ± 11 98 ± 9* 93±12**
Kidney weight/ BW 
(mg/g) (n=12-
18/group)
8.7 ± 0.6 8.5 ± 0.6 9.9 ± 1.4* 10±1.2**
Glomerular volume 
(µm3)
(n=7-12/group, 
average 30 glomerular 
determinations per 
animal)
215480 ± 45972 231523 ± 38702 193193 ± 22518 239640 ± 51064
Page 26 of 50
For Peer Review Only
Diabetes
27
Figures’ legends:
Fig. 1: sNogo-B overexpression in the circulation ameliorates diabetic glomerulopathy.
AAV-sNogo-B administration significantly increases plasma sNogo-B levels (a, n=12-
21/group)(measured at sacrifice, 12-14 weeks post diabetes induction)(ND-GFP vs ND-
sNogo-B, D-GFP vs D-sNogo-B, ~p≤0.0001) and ameliorates diabetes-mediated albuminuria 
(b, n=12-17/group), and hyperfiltration, measured as change in creatinine clearance (c, n=6-
8/group). Diabetes was paralleled by an increase in sNogo-B in the urine (d, n=6/group), no 
differences were observed between mice with GFP or sNogo-B overexpression within the ND 
or D group (ND-GFP vs D-GFP, *p≤0.02; ND-sNogo-B vs D-sNogo-B, **p≤0.002; D-GFP vs 
D-sNogo-B, #p≤0.04). (a, b, d) Kruskal-Wallis and Mann-Whitney test (median interquartile 
range); (c) ANOVA with LSD post-hoc test (mean±SD). AAV-GFP treated mice black circles 
(), AAV-sNogo-B treated mice white circles ().
Fig. 2: sNogo-B overexpression in the circulation ameliorates diabetes-mediated 
glomerular ECs proliferation, reduction in glycocalyx lectin content and podocyte loss.
(a) GECs proliferation was detected by CD31+/Ki67+ cells (white arrow). Diabetes significantly 
increases the average number of glomerular CD31+/Ki67+ cells by 7-fold which was reduced 
by sNogo-B overexpression in the circulation (b, n=8-12/group, average of 30-40 
glomeruli/animal). Diabetes led to a 20% reduction in the thickness of the glycocalyx 
(assessed as lectin content) which was prevented by sNogo-B overexpression in the 
circulation (c, n=5/group, with 10-15 capillary loops studied per mouse). Similarly, diabetes-
mediated glomerular podocytes loss was ameliorated by sNogo-B overexpression in the 
circulation (d, n=7-11/group). Elevated sNogo-B circulating levels had no effect on the 
diabetes-mediated increase in mesangial volume fraction (Vvmes)(e, n=9-12/group) or 
glomerular basement membrane (GBM) thickness (f, n=7-11/group).
(ND-GFP vs D-GFP, *p≤0.02; D-GFP vs D-sNogo-B, #p≤0.01; ND-sNogo-B vs D-sNogo-B, 
**p=0.02).  ANOVA with LSD post-hoc test (mean±SD) for all comparisons. AAV-GFP treated 
mice black circles (), AAV-sNogo-B treated mice white circles ().
Fig. 3: sNogo-B overexpression in the circulation ameliorates diabetes-mediated VEGF-
A/VEGFR2 signaling and eNOSSer1177 phosphorylation in kidney cortex lysate.
Diabetes-induced kidney cortex VEGF-A expression (a, n=11-14/group, in duplicate) and 
phosphorylated p-VEGFR2Tyr1173 (b, n=7/group, in duplicate) was blunted in diabetic mice with 
sNogo-B overexpression in the circulation (ND-GFP vs D-GFP, *p≤0.003; D-GFP vs D-sNogo-
B, #p≤0.03). Angpt-1/Angpt-2 ratio (c, n=7-8/group, in duplicate) was reduced in diabetes 
(ND-GFP vs D-GFP; ND-sNogo-B vs D-sNogo-B, *,**p≤0.03) but not altered by elevated 
sNogo-B circulating levels. The diabetes-mediated increase in ratio of phosphorylated p-
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eNOSSer1177/total eNOS was prevented by sNogo-B overexpression in the circulation (d, n=8-
10/group, ND-GFP vs D-GFP, *p=0.017; D-GFP vs D-sNogo-B, #p=0.05). (e) Representative 
data showing western blotting for phosphorylated p-eNOSSer1177, total eNOS and α-tubulin as 
housekeeping gene. ANOVA with LSD post-hoc test (mean±SD) for all comparisons. AAV-
GFP treated mice black circles (), AAV-sNogo-B treated mice white circles ().
Fig. 4: sNogo-B overexpression in the circulation modulates diabetes-mediated 
AKTSer473 and GSK3βSer9 phosphorylation, while preventing diabetes-mediated β-
catenin upregulation.
Diabetes was paralleled by a 2/3-fold increase in the ratio of phosphorylated p-AKTSer473/total 
AKT (a, n=6-8/group), a significant elevation of the ratio of phosphorylated p-GSK3βSer9/total 
GSK3β (b, n=8/group) and increased total β-catenin levels (c, n=8/group) in kidney cortex 
lysates (ND-GFP vs D-GFP, *p≤0.007). Diabetes-mediated AKT and GSK3β phosphorylation 
and upregulation β-catenin levels were partially or totally prevented by sNogo-B 
overexpression in the circulation (D-GFP vs D-sNogo-B, #p≤0.04; ND-sNogo-B vs D-sNogo-
B, **p=0.0001). ANOVA with LSD post-hoc test (mean±SD) for all comparisons. AAV-GFP 
treated mice black circles (), AAV-sNogo-B treated mice white circles ().
Fig. 5. Full-length Nogo-B is expressed in glomeruli and sNogo-B overexpression in 
the circulation prevents diabetes-mediated Nogo-B downregulation.
(a) Electron microscopy showing the ultrastructure of the kidney glomerulus containing 
podocytes (POD), endothelial cells (EC) and the glomerular basement membrane (GBM). 
Immunogold labelling showed positive full-length Nogo-B expression in podocytes (black 
arrowheads) (i) and endothelial cells (black arrows) (ii). Collecting duct (medullary section) 
(iii) are used as positive control and negative control (omission of first antibody) is shown in 
(iv). Bar is 500 nm. (b) Positive signal for Nogo-B (right panel) is observed by 
immunohistochemistry both in glomerular cells (black arrows) and in the cortical collecting 
duct (positive internal control - red arrows) (magnification x40). Negative control-omission first 
anti-Nogo-B antiserum (left panel). (c) Full-length Nogo-B protein expression was 
downregulated in kidney cortex cell lysate and isolated glomeruli of diabetic mice and was 
prevented by AAV-sNogo-B overexpression in the circulation (c, n=10-13/group fort cortex 
lysate, n=4-5 for isolated glomeruli, ND-GFP vs D-GFP, *p≤0.045; D-GFP vs D-sNogo-B, 
#p≤0.015). (d) NgBR was detected in isolated glomeruli, no effect of diabetes or sNogo-B 
overexpression was noted. (e) Nogo-B expression (brown staining) was detected by 
immunohistochemistry in kidney biopsies from patients with diabetic nephropathy (DN) and 
thin basement membrane nephropathy (TBMN). Positive staining in the cortical collecting 
ducts serves as positive internal control (red arrows). Bar is 100 µm. Quantitative data 
showing the area of the glomerular tuft containing positive Nogo-B staining (n=10/group for 
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both TBMN and DN with an average score from 10 glomeruli obtained for each biopsy, TBMN 
vs DN, *p=0.0001). (c, d) ANOVA with LSD post-hoc test (mean±SD). AAV-GFP treated mice 
black circles (), AAV-sNogo-B treated mice white circles (); (e) Unpaired t-test (mean±SD).
Fig. 6: Incubation of GECs with high glucose and/or VEGF-A in vitro results in 
downregulation of full-length Nogo-B and parallel increase in sNogo-B secretion in the 
supernatant.
Fully differentiated GECs were incubated with normal (NG) or high (HG) glucose for 72h in 
the absence (vehicle: VEH) or presence of VEGF-A (50 ng/ml). Full-length Nogo-B protein 
expression was significantly downregulated by HG and/or VEGF-A (a, n=5-6, in duplicate). 
Conversely HG and/or VEGF-A was paralleled with an increase in sNogo-B levels, expressed 
as pg/ml.µg of cell protein, in the supernatant (b, n=4-5 in duplicate)(NG vs HG, NG vs VEGF-
A, NG vs HG+VEGF-A, *p≤0.03). (a) ANOVA with LSD post-hoc test (mean±SD); (b) Kruskal-
Wallis and Mann-Whitney test (median and interquartile range). NG+VEH black circles (), 
HG+VEH white circles (), NG+VEGF-A black square (), HG+VEGF-A white square ().
Fig. 7: sNogo-B overexpression in the supernatant ameliorates impaired angiogenesis 
in HUVEC cultured with serum from patients with type-1 diabetes mellitus and DN. 
(a) HUVEC transfected with either ADV-control (cont) or ADV-sNogo-B (sNogo-B) were 
seeded onto Matrigel for tube formation assay. HUVEC were then incubated with media 
containing (4% vol/vol) sera obtained from blood of patients with type-1 diabetes mellitus 
susceptible (DN+) or protected (DN-) towards the progression of DN (a, n=16-18/group, in 
duplicate).  An impairment in tube length (b) and number (c) was observed in HUVEC cultured 
with DN+ serum (ADV-control, DN+ vs DN-, *p≤0.04) was prevented by sNogo-B 
overexpression (DN+, ADV-control vs ADV-sNogo-B, #p≤0.02). (d) sNogo-B levels in the 
supernatant of HUVECs transfected with ADV-control (cont) or ADV-sNogo-B (sNogo-B) 
vectors (ADV-control vs ADV-sNogo-B within DN- and DN+, ~p≤0.0001, n=16-17/group, in 
duplicate). (b, c) ANOVA with LSD post-hoc test (mean±SD); (d) Kruskal-Wallis and Mann-
Whitney test (median and interquartile range). ADV-control treated cells black circles (), 
ADV-sNogo-B treated cells white circles ().
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Supplemental Material 
 
Generation of adeno-associated viral (AAV) vectors 
The AAV-sNogo-B vector was generated by cloning the previously described (1) HindIII/XhoI 
200aa N-terminus Nogo-B (sNogo-B) sequence cDNA in frame with the signal secretory 
sequence of placental alkaline phosphatase (AP), His tag, and placental AP coding region 
(gift of W Sessa, Yale University, CT, USA) downstream of the CMV promoter in AAV/DJ 
containing a hybrid capsid derived from eight wild-type AAV serotypes (2).  
As control vector, we utilised an identical vector (AAV/DJ) driving (CMV promoter) the 
expression of green fluorescent protein (GFP). Viral particles were amplified commercially 
(Vectors Bioloab, Great Valley Parkway, Malvern, PA, USA). 
AAV-sNogo-B and AAV-GFP vectors were administered intravenously at a dose of 1x1011 GC 
(gene copies) per mouse of 20gr (2). 
 
Generation of adenoviral (ADV) vectors 
Adenovirus (ADV)-sNogo-B vector (generated with the AdEasy Adenoviral Vector Systems, 
Agilent, Oxford, UK) expressed the described 200aa N-terminus Nogo-B (sNogo-B) sequence 
cDNA in frame with the signal secretory sequence of placental alkaline phosphatase (AP), His 
tag, and placental AP coding region (1)(gift of W Sessa, Yale University, CT, USA) under 
regulation of the CMV promoter, and was propagated in HEK293 cells and purified as 
previously described (3). As control ADV vector, we utilised an identical construct lacking 
sNogo-B cDNA. In experiments confluent cells were transfected with 100 multiplicity of 
infection (MOI). 
 
Immunofluorescence 
GECs proliferation (4). Frozen mouse kidneys, acetone fixed, 4μm sections were incubated 
with Alexa Fluor 594 conjugated anti-CD31 antibody (1:50)(Biolegend, London, UK) and Alexa 
Fluor 488 conjugated anti-Ki67 antibody (1:100)(Biolegend, London, UK) in PBS 1%BSA 
overnight in a humidified chamber at 4°C. Omission of the antisera and incubation with PBS 
1%BSA served as a negative control. Sections were then washed in PBS and mounted with 
Vectashield antifade mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories, Peterborough, UK). Glomerular Ki67/CD31 and CD31 positive ECs per 
glomerulus were visualised with Olympus BX51 fluorescent microscope. 
Endothelial glycocalyx determination. Frozen kidney 4μm sections were obtained from each 
animal and left to air-dry overnight at RT. Kidney sections were then fixed in acetone at -20°C 
for 10min and left to air-dry for 20min. Sections were incubated overnight at 4°C with 0.2μg/ml 
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FITC-conjugated lectin from Lycopersicon Esculentum Agglutinin (LEA)(Sigma)(1:2500) in 
PBS 1%BSA for glycocalyx staining and 1μg/ml mouse monoclonal CD31 antibody (Santa 
Cruz Biotechnology, Heidelberg, Germany)(1:1000) in PBS 1%BSA for ECs staining. 
Following this, sections were incubated for 1h with 1μg/ml (1:1000 dilution in PBS 1%BSA) 
Alexa Fluor 568-conjugated goat anti-mouse IgG (ThermoFisher Scientific, Oxford, UK). Slides 
were washed between steps with PBS and mounted with Vectashield antifade mounting 
medium with DAPI (Vector Laboratories, Peterborough, UK). 
Capillaries were then analysed by confocal microscopy (Eclipse Ti-E Inverted, Nikon, 
https://www.kcl.ac.uk/innovation/research/corefacilities/smallrf/nikon/index.aspx) with NIS-
Elements Viewer elements software. Multiple glomeruli in each kidney sample were captured 
at 40x magnification. 
To establish the glycocalyx thickness, images were analysed with ImageJ software (NIH-
Bethesda, MD, USA). Glomerular capillary loops were identified in each glomeruli and 
fluorescent intensity plots, for CD31 and intraluminal LEA, were processed from a line 
perpendicular to the capillary wall. The distance from the peak of CD31 signal to the half-
maximal intensity of the intraluminal LEA peak, representing the endothelial glycocalyx 
thickness, was expressed in µm as previously described (5; 6). 
 
Electron microscopy and glomerular ultrastructure analysis 
Mesangial volume fraction, as an index of glomerular extracellular matrix deposition, GBM 
thickening, were studied with electron microscopy stoichiometry techniques as described (7; 
8).  
Specifically, mesangial volume fraction was estimated using point counting. A grid of coarse 
and fine points (ratio 1:8) was overlaid on each image. The number of coarse points hitting the 
reference space (the glomerular tuft as defined by the minimal string polygon) and fine points 
on mesangium were counted. The volume fraction of mesangium was calculated as follows: 
Vv = Pmes/(Pglom * 8) where Pmes is the number of points on mesangium and Pglom is the 
number of points on the glomerular tuft. 
Glomerular basement membrane width was measured directly on images using the line tool. 
In order to select, without bias, the portion of GBM that was measured, a grid of lines was 
superimposed on each image. The GBM was measured wherever a grid line intersected with 
the endothelium, perpendicular to the endothelium. 
Podocyte number was estimated from electron micrographs by first estimating podocyte 
density (Nv) using the method of Weibel and Gomez (9) NV = K/b ÖNA3/Vv, where NA is the 
profile density of the particles, Vv is the volume fraction of the particles, K is a size distribution 
coefficient and b is a shape constant.  For most biological applications the size distribution 
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coefficient, K, varies between 1 and 1.05 and can therefore be neglected. The shape constant 
used for podocyte nuclei is for an ellipsoid, 1.55. Podocyte density was multiplied by glomerular 
volume to give podocyte number N = NV * V.  
This method has been shown to be comparable to the disector/fractionator method (8), which 
is considered to be the gold-standard. 
Glomerular volume was calculated as described previously in rodents by glomerular diameter 
determination in paraformaldehyde fixed tissue (10). 
 
sNogo, VEGF-A, Angpt1/2 and VEGFR2Tyr1173 phosphorylation ELISA 
All ELISA experiments were conducted in duplicate on plasma, urine and cell culture media 
for sNogo-B. For cortex VEGF-A, Angpt1/2, and VEGFR2Tyr1173 phosphorylation, 50μg of total 
cortex cells lysate was assessed in duplicate for each animal. The ELISA kit utilised for 
VEGFR2 phosphorylation recognises the human VEGFR2Tyr1175 known to be identical to 
residue VEGFR2Tyr1173 in the mouse (11). 
 
Immunoblotting 
Cells or tissues (mouse renal cortex) were homogenised in RIPA lysis buffer (ThermoFisher 
scientific, Oxford, UK) containing proteases and phosphatases inhibitors, and lysates were 
separated by 10% SDS-PAGE. Immunoreactive bands were visualized with 
chemiluminescence and quantified using densitometry with a-tubulin or b-actin as house-
keeping proteins control as previously described (12). 
 
Culture and characterization of mouse lung endothelial cells 
Primary lung ECs were isolated from adult C57BL/6J mice and cultured as previously 
described (13; 14) after two cells’ sorting with CD31 antisera (monoclonal rat anti-Mouse 
CD31 antiserum, BD Pharmingen/Biosciences, Wokingham, UK) and sheep anti-rat IgG 
coated Dynabeads (M-450 Dynabeads, Dynal Biotech, ThermoFisher Scientific, Oxford, UK). 
Lung ECs were cultured up to three passages. Lung EC characterisation was conducted with 
immunofluorescence, in 4% paraformaldehyde fixed (10min) permeabilised (0.5% triton in 
PBS 10min) EC using anti eNOS rabbit polyclonal antiserum (Santa Cruz Biotechnology, 
Heidelberg, Germany) at 4°C for 12h followed by incubation with anti-rabbit Alexa 594 
secondary antibody respectively (ThermoFisher Scientific, Oxford, UK). Slides were washed 
between steps with PBS and mounted with Vectashield antifade mounting medium with DAPI 
(Vector Laboratories, Peterborough, UK). These cells were utilised as positive control for the 
expression of NgBR (15). 
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Human GECs (gift from S Satchell, University of Bristol, UK) were cultured in EGM-2MV 
medium (Lonza, CC-3202) and differentiated as previously described (16). 
 
Immunoprecipitation (IP) and proximity ligation assay (PLA) experiments 
For IP experiments, whole protein cell lysates were obtained from human GECs 
overexpressing sNogo-B (6xHis-Tag/sNogo-B construct) and incubated with either rabbit 
polyclonal anti NgBR antisera (1μg)(Novus Biological, Oxford, UK), or anti 6xHis-Tag (1μg) 
mouse monoclonal antiserum (ThermoFisher Scientific, Oxford, UK), or vehicle IgG (1μg). 
Immunoprecipitates were then obtained by incubation with protein G-coated magnetic beads 
as per standard protocol (Universal Magnetic Co-IP Kit, Active Motive). Immunoblotting was 
then conducted with anti 6xHis-Tag and anti NgBR antisera. 
For the PLA experiments (Duolink Sigma, Gillingham, UK) we followed the manufacturer 
instructions. NgBR-sNogo-B interaction was studied with PLA probes (one PLUS and one 
MINUS) with hosts corresponding to each of the primary antibodies (anti-rabbit and anti-
mouse), and interaction visualised with immunofluorescence following manufacturer 
instructions (Duolink® In Situ Red Starter Kit Mouse/Rabbit). GECs were visualised with 
mouse monoclonal anti VE-cadherin antibody (Santa Cruz Biotechnology, Heidelberg, 
Germany) in PBS 1%BSA and secondary goat anti mouse Alexa 488 (ThermoFisher 
Scientific, Oxford, UK). Negative controls for the PLA consisted of omission of each of the two 
primary antibodies used (one negative control without anti N-terminus NgBR, and one without 
anti 6xHis-Tag, not shown). 
 
Nogo-B immunogold staining in glomeruli 
Nogo-B immunogold staining was conducted in mouse renal cortex tissue fixed in 2% 
paraformaldehyde.  Briefly ultrathin sections (70nm) were incubated overnight at 4°C with 
sheep polyclonal anti-Nogo-B (N-terminus) antibody (R&D System, Abingdon, UK) diluted 
1:200 in phosphate buffer saline (PBS), 0.5% bovine serum albumin (BSA), followed by gold-
conjugated goat anti-sheep IgG (1:20) in PBS 0.5%BSA for 1h at RT.  Grids that had not been 
incubated with primary antibody were used as negative controls.  Samples were examined with 
a Philips CM100 Transmission electron microscopy. 
 
Nogo-B immunohistochemistry  
Human tissue: Human archival formalin-fixed/paraffin embedded kidney biopsies, obtained 
from the National Clinical Research Centre of Kidney Disease and Guangdong Provincial 
Institute of Nephrology, Guangzhou-China between 2013 to 2015, were used for Nogo-B 
immunohistochemistry staining. The study was specifically approved by the Ethics Committee 
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of National Clinical Research Centre of Kidney Disease and Guangdong Provincial Institute 
of Nephrology in Guangzhou, China. 
The indications for performing the renal biopsy in patients with type 2 diabetes (T2DM) 
followed internal guidelines whereby renal biopsy was indicated in the presence of 
macroproteinuria with or without microscopic haematuria or rapid progressive decline in renal 
function. The indication for renal biopsy for patients with thin basement membrane 
nephropathy (TBMN) was microscopic haematuria. Histological diagnosis of diabetic 
nephropathy (DN) and TBMN had been undertaken by two independent renal pathologists, 
and no evidence of other renal diseases and no history of assumption of herbal medicines or 
other nephrotoxic agents was noted. Patients characteristic are described in Table 1. 
Two-µm thick paraffin sections were studied using the standard streptavidin-biotin complex 
method using a specific sheep polyclonal anti Nogo-B N-terminus antibody (1:50)(R&D 
System, Abingdon, UK) at 4°C for 12h followed by incubation with biotin-conjugated goat anti-
sheep secondary antibody (1:200, Dako; Ely, UK) for 30min at RT and peroxidase reaction 
with 3,3’-diaminobenzidine tetra-hydrochloride (Dako, Carpinteria, CA, USA). Nuclei were 
counterstained with haematoxylin and slides mounted in Permount mounting medium 
(eBioscience, San Diego, CA, USA). For visualization, another set of sections was 
counterstained with Periodic Acid-Schiff. Staining of cortical collecting duct served as internal 
positive controls for Nogo-B staining.  Omission of primary antibody served as a negative 
control (not shown). 
Nogo-B expression level was assessed semi quantitatively. Glomerular boundaries were 
defined by external perimeter of the capillary loops.  The proportional area occupied by 
immunoreactive Nogo-B was calculated using a computer assisted KS-300 image analysis 
system (Carl-Zeiss, Jena, Germany) connected to an BX51 microscope (Olympus, Tokyo, 
Japan) and a KY-F55B colour video camera (JVC, Tokyo, Japan).  Determinations were made 
at the same light microscope intensity. 
Mouse tissue: similar immunohistochemistry techniques were utilised for mouse kidney tissue. 
Omission of first antiserum served as negative control and slide were stained with 
haematoxylin as per standard protocol. 
 
Culture of Human umbilical vein endothelial cells (HUVEC) and tube formation assay 
HUVECs were cultured with EGM-MV medium (PromoCell, Heidelberg, Germany) and 
cultured up to third passage. After transfection (ADV-sNogo-B and ADV-control vector) cells 
were trypsinised from tissue culture flasks and then plated in 96 well plates (5000 cells/well) in 
EGM basal media containing patients’ sera (4% vol/vol)(see below) and tube formation 
performed on Matrigel (BD Biosciences, UK) previously described.  
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Patients sera was collected, after consent, from patients with type-1 diabetes (T1DM) with or 
without DN identified within the Department of Diabetes and Endocrinology at Guy’s and St 
Thomas NHS foundation Trust, London, UK.  T1DM was defined as onset before age 35, 
insulin therapy within 6 months of diagnosis and no breaks in insulin therapy for more than 6 
months (17).  DN was defined as albuminuria or history of clinical albuminuria (18) in at least 
two of three overnight urine collections, in the absence of other causes of renal damage or 
urinary tract infections, but in the presence of retinopathy. The patients with T1DM and 
minimal disease progression were defined as patients with ≥20 years of diabetes duration, 
normoalbuminuria, normal serum creatinine, and normal blood pressure (£130/80mmHg).  All 
diabetic patients had normal to mild impairment of renal function (eGFR, assessed with MDRD 
(19) formula, >60 ml/min/1.73m2) with (DN+) or without (DN-) presence or history of 
microalbuminuria (20).  Statin treatment was higher in the DN+ group; all recruited patients 
were non-smokers, and absence of history of acute ischemic events (e.g. myocardial 
infarction, stroke) was ensured in all patients (Table 2).  The study was approved by the 
national Health Research Authority. Blood was collected in the non-fasting state and serum 
was stored at -80°C. 
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Figures 
 
 
 
 
 
Fig. 1: Schematic representation of viral vectors transcription cassettes (not in scale). 
Schematic graphical representation of transcription cassette utilized in the AAV (a) and ADV 
(b) viral vectors. In (c) is presented the estimated molecular weight of the transgene (~80 
kDA) in total cell lysate obtained from HUVEC transfected with ADV-control or ADV-sNogo-B 
vector. 
  
AAV: Adeno associated vector.
ADV: Adenoviral vector.
CMV promoter: citomegalovirus promoter.
sec: secretory signal alkaline phosphatase.
AP: alkaline phosphatase (~1.6 Kb, ~60-65 
kDA), from pSEAP (Clontech).
6xHis: Histidine Tagx6 (~1 kDA).
Poly-A: polyadenylation signal.
Nogo-B N-term (1-200aa): predicted 15-20 
kDA.
sec 6xHis AP Nogo-B N-term (1-200aa) Poly-ACMV promoter
CMV promoter GFP Poly-A
(a) AAV vector expression cassette
sec Poly-ACMV promoter
(b) ADV vector expression cassette
6xHis AP
30 kDA
58 kDA
full length Nogo-B
(~49kDA)
6xHis-Tag/AP/sNogo-B
(~80 kDA)
Total cells lysate of HUVEC transfected
with either ADV-control or ADV-sNogo-B
vector (immunoblotting with anti N-
terminus Nogo-B antisera).
ADV- control
vector
ADV- sNogo-B
vector
sec 6xHis AP Nogo-B N-term (1-200aa) Poly-ACMV promoter
(c)
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Fig. 2: Representative EM scanning images from control and diabetic mice with or 
without sNogo-B overexpression in the circulation. 
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Fig. 3: sNogo-B interacts with NgBR in GECs in vitro. 
(a) sNogo-B/NgBR interaction was demonstrated with immunoprecipitation in 6xHis-
Tag/sNogo-B overexpressing human GECs. Western blot analysis for His-Tag (left blots) and 
NgBR (right blots) after NgBR and His-Tag immunoprecipitation from total GECs’ lysate. (Lane 
1. and 6. total GECs’ lysate, 4. and 10. no IP, 5. and 11. control IgG, lane 7 mouse lung ECs 
(positive control for NgBR expression).  (b) ECs’ sNogo-B/NgBR interaction was visualised 
(red/orange dots) with proximity ligation assay in non-permeabilized human GECs after 1 min 
incubation with “conditioned media” containing 6xHis-Tag/sNogo-B protein (~6000 pg/ml); no 
signal was observed in negative controls where the VE-cadherin positive staining (green) was 
visible. 
 
 
 
 
 
 
a
non permeabilized 
human GECs
non permeabilized 
human GECs, negative control
(VE-cadherin+)
human GECs
kDa 150 -
100 -
75 -
IP:     - His NgBR   - IgG
His-Tag Ab:    +      +      +       +       +
His-Tag
sNogo-B
IP:     - - His   NgBR   - IgG
NgBR Ab:    +       +         +        +       +      +
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37 -
25 - NgBR
b
1.     2.    3.      4.      5.                                                           6.     7.         8.     9.   10.  11.
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Fig. 4: Podocytes express NgBR in vitro 
  
25 kDa NgBR
1. , 2. - diffentiated human podocytes
3. - proliferating human podocytes
4. , 5. - kidney cortex total cells lysate (positive control)
1.     2.    3.             4.    5.
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Tables: 
 
 
 
Table 1: Patients with DN or TBMN clinical characteristics. 
Renal biopsies obtained from patients with T2DM and TBMN were studied. eGFR calculated 
with MDRD formula. Data are expressed as mean±SD, *median [interquartile range]. 
 
 
 
 
 
 
 
 
 
 
  
Controls 
(TBMN) Patients with diabetes 
Sex 1M  9F 8M  2F 
Age (years) 33 ± 5 48 ± 10 
Duration Diabetes (years)  5.8 ± 2.7 
HbA1c % (mmol/mol)  7.3 (56.0) ± 1.2 (13.6) 
BP systolic (mmHg) 121 ± 10 144 ± 20 
BP diastolic (mmHg) 74 ± 10 89.7 ± 10 
eGFR (ml/min/1.73 m2) 117 ± 8.7 107 ± 14 
Proteinuria (g/24h)* 0.13 [0.08-0.21] 2.17 [0.88-4.76] 
Retinopathy (%)  40 
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 T1DM / DN- T1DM / DN+ 
Sex 8M  9F 11M  7F 
Age (years) 46.8 ± 12.2 53.3 ± 10.8 
Duration Diabetes 
(years) 31 ± 11.4 30.4 ± 10.2 
HbA1c % (mmol/mol) 7.9 (62.7) ± 1.2 (13.0) 7.8 (61.8) ± 1.1 (12.6) 
BP systolic (mmHg) 130.2 ± 15.1 140.8 ± 13.1 
BP diastolic (mmHg) 76.6 ± 8.7 75.9 ± 6.8 
Cholesterol (mmol/L) 4.7 ± 0.8 4.05 ± 0.6 
eGFR (ml/min/1.73 m2) 101.7 ± 22.6 81.8 ± 32.2 
ACR (g/mol)* 0.8 [0.4-2.1] 1.15 [0.6-9.3] 
RAAS inhibition (%) 0 100 
Statin (%) 29 70 
Retinopathy (%) 100 100 
Smoking (%) 0 0 
sNogo-B (pg/ml)* 420.7 [270.6-883.2] 463.8 [293.5-658.9] 
 
Table 2: Patients with type-1 diabetes, with (DN+) or without (DN-) history of 
albuminuria, clinical characteristics. 
Patients with type-1 diabetes (T1DM) with (DN+) or without (DN-) history of albuminuria were 
enrolled in the study. eGFR calculated with MDRD formula. Data are expressed as mean ± 
SD, *median [interquartile range]. 
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